CUG288
/ Cugene
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 01, 2021
TILKine-2: A novel best-in-class tumor infiltrating lymphocyte (TIL) targeting engineered IL-2 with superior pre-clinical efficacy and safety for immunotherapy of cancer.
(SITC 2021)
- "Conclusions By targeting TILs, TILKine-2 demonstrated robust anti-tumor efficacy by preferentially inducing proliferation, expansion, and activation of intra-tumoral lymphocytes while reducing systemic toxicity and improving therapeutic window. In conclusion, TILKine-2 is a promising therapeutic agent for clinical development."
IO biomarker • Preclinical • Genito-urinary Cancer • Melanoma • Oncology • Renal Cell Carcinoma • Solid Tumor • CD8 • GZMB • IFNG • IL2
1 to 1
Of
1
Go to page
1